SEC Tracker
Get the app

Kyverna Therapeutics KYTX

Kyverna Therapeutics Q3 FY24: net loss $34.5M; diluted EPS −$0.80

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Kyverna Therapeutics reported for Q3 FY24, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$34.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$0.80No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$104.7MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  4. Cash from operations−$27.5MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Kyverna Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Quince Therapeutics QNCX public float $64M, Jun 30, 2025
  2. Elutia ELUT public float $65M, Jun 30, 2025
  3. Tevogen TVGN public float $64M, Jun 30, 2025
  4. Neumora Therapeutics NMRA public float $63M, Jun 30, 2025
  5. Tenaya Therapeutics TNYA public float $63M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.